Ubs Oconnor LLC Axogen, Inc. Transaction History

Ubs Oconnor LLC

$1.46 Billion
Q3 2024

A detailed history of Ubs Oconnor LLC transactions in Axogen, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 141,663 shares of AXGN stock, worth $2.69 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

141,663

Holding current value

$2.69 Million

% of portfolio

0.14%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$7.52 - $14.69 $30,741 - $60,052	4,088 Added 2.97%	141,663 $1.99 Million
Q4 2023 Feb 14, 2024	SELL	$3.61 - $7.76 $366,851 - $788,578	-101,621 Reduced 42.48%	137,575 $939,000
Q3 2023 Nov 14, 2023	SELL	$4.68 - $9.26 $174,971 - $346,203	-37,387 Reduced 13.52%	239,196 $1.2 Million
Q2 2023 Aug 14, 2023	BUY	$8.5 - $10.38 $2.35 Million - $2.87 Million	276,583 New	276,583 $2.53 Billion
Q1 2023 May 15, 2023	BUY	$7.53 - $10.95 $243,550 - $354,166	32,344 Added 14.26%	259,214 $2.45 Million
Q4 2022 Feb 14, 2023	BUY	$9.44 - $13.09 $13,149 - $18,234	1,393 Added 0.62%	226,870 $0
Q3 2022 Nov 14, 2022	BUY	$8.14 - $12.25 $325,600 - $490,000	40,000 Added 21.57%	225,477 $2.69 Billion
Q2 2022 Aug 12, 2022	BUY	$6.99 - $10.0 $492,634 - $704,770	70,477 Added 61.28%	185,477 $1.52 Million
Q1 2022 May 16, 2022	BUY	$7.26 - $10.7 $834,900 - $1.23 Million	115,000 New	115,000 $913,000

Others Institutions Holding AXGN

# of Institutions

163

Shares Held

36.1M

Call Options Held

230K

Put Options Held

400

First Light Asset Management, LLC Edina, MN

4.09M
Shares

$77.6 Million
5.0% of portfolio
Black Rock Inc. New York, NY

3.25M
Shares

$61.6 Million
0.0% of portfolio
Soleus Capital Management, L.P. Greenwich, CT

3.01M
Shares

$57 Million
3.58% of portfolio
Morgan Stanley New York, NY

2.9M
Shares

$55 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

2.43M
Shares

$46 Million
0.0% of portfolio

View Full List

About Axogen, Inc.

Ticker AXGN
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 42,283,700
Market Cap $802M
Description
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...

More about AXGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account